Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial

PURPOSE: In patients with hormone-dependent postmenopausal breast cancer, standard adjuvant therapy involves 5 years of the nonsteroidal aromatase inhibitors anastrozole and letrozole. The steroidal inhibitor exemestane is partially non–cross-resistant with nonsteroidal aromatase inhibitors and is a...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Goss, Paul E., Ingle, James N., Pritchard, Kathleen I., Ellis, Matthew J., Sledge, George W., Budd, G. Thomas, Rabaglio, Manuela, Ansari, Rafat H., Johnson, David B., Tozer, Richard, D'Souza, David P., Chalchal, Haji, Spadafora, Silvana, Stearns, Vered, Perez, Edith A., Liedke, Pedro E.R., Lang, Istvan, Elliott, Catherine, Gelmon, Karen A., Chapman, Judy-Anne W., Shepherd, Lois E.
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3612593/
https://ncbi.nlm.nih.gov/pubmed/23358971
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.44.7805
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares